Definitive Healthcare Corp. Stock Price, News & Analysis

Definitive Healthcare reported Q3 2024 financial results with revenue of $62.7 million, a 4% decrease from Q3 2023. Net loss was $(187.8) million, including goodwill impairment charges of $228.2 million. Adjusted net income rose to $15.4 million from $14.6 million, while adjusted EBITDA fell 5% to $20.6 million. Cash flow from operations was $19.4 million, and unlevered free cash flow was $24.3 million. The company announced a $100 million stock repurchase program starting in 2025. Customer base grew to 530 enterprise clients. CFO Richard Booth will leave by June 1, 2025. Q4 2024 revenue guidance is $60.0-$61.0 million, adjusted net income $10.5-$11.5 million, and full-year 2024 revenue is expected to be $250.0-$251.0 million.

Definitive Healthcare (Nasdaq: DH) has scheduled its third quarter 2024 financial results announcement for Thursday, November 7, 2024, after market close. The healthcare commercial intelligence company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the results. Investors can access the live audio webcast on the company's IR website and join via phone using domestic (877-358-7298) or international (+1-848-488-9244) dial-in numbers. A replay will be available until December 7, 2024.

Definitive Healthcare (Nasdaq: DH) has launched Monocl Conferences, a solution designed to enhance conference planning and participation for life science organizations. This intuitive platform provides medical affairs, marketing, and conference planning teams with rich, contextualized conference data and access to key experts.

Key features include:

• Visualized conference data dashboard
• Searchable conference insights
• Comparable data for monitoring trends

Monocl Conferences offers quick access to presentations, competitor analysis, social media insights, and details about centers of excellence. It aims to streamline planning, drive strategic engagement, and support organizations in delivering innovative therapies and medical devices to improve patient outcomes.

Definitive Healthcare (Nasdaq: DH) has launched Market Forecast, a predictive analytics solution designed to help healthcare organizations identify high-growth markets and service line opportunities. This new tool provides three, five, and 10-year market trend projections to strengthen strategic planning around future demand and growth opportunities.

Market Forecast aims to empower business development teams, service line leaders, and strategy executives by delivering year-over-year growth rate and market demand projections. This enables healthcare organizations to:

• Drive improved patient acquisition and retention
• Plan market expansion
• Allocate resources more effectively

The solution is particularly valuable for academic medical centers and other healthcare providers looking to identify services with the greatest potential for future growth, even when current volumes may not reflect that opportunity.

Definitive Healthcare Corp. (Nasdaq: DH), a leader in healthcare commercial intelligence, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. Rick Booth, the company's Chief Financial Officer, is scheduled to present on Thursday, September 5, 2024, at 8:30 a.m. Eastern Time.

Investors and interested parties can access a live webcast of the presentation through the Events page on Definitive Healthcare's investor relations website at https://ir.definitivehc.com/. For those unable to attend the live event, a replay of the webcast will be available for a time after the presentation.

Definitive Healthcare (Nasdaq: DH) has expanded its Population Intelligence platform to serve a wider range of industries selling into healthcare. The platform now supports businesses in sectors like advertising, marketing, telehealth, staffing, and medical supply to enhance marketing campaigns and digital advertising performance.

Population Intelligence combines clinical and consumer data on over 250 million unique consumers aged 18+, offering 300+ clinical propensity, social determinants of health, and media channel models. This allows businesses to create precise audience segments and launch targeted marketing campaigns, driving efficient consumer activation.

The platform enables teams to segment markets, build campaign audiences, and activate audiences for digital advertising. It integrates with organizations' internal systems while keeping first-party data secure, promoting compliance with data privacy standards.

Definitive Healthcare Corp. (Nasdaq: DH) reported financial results for Q2 2024. Revenue grew 5% year-over-year to $63.7 million. The company incurred a net loss of $306.2 million, primarily due to goodwill impairment charges of $363.6 million. However, Adjusted EBITDA increased 21% to $20.9 million, representing 33% of revenue.

Key highlights include:

• Adjusted Net Income: $14.2 million
• Cash Flow from Operations: $14.0 million
• Unlevered Free Cash Flow: $21.5 million
• Enterprise customers grew by 32 (6% YoY) to 537

For Q3 2024, DH expects revenue between $61.0-$62.5 million and Adjusted EBITDA of $17.5-$19.0 million. Full-year 2024 guidance projects revenue of $247-$251 million and Adjusted EBITDA of $74-$77 million.

Definitive Healthcare Corp. (Nasdaq: DH), a leader in healthcare commercial intelligence, has announced the timing for its second quarter 2024 financial results conference call and webcast. The company will report its financial results for the quarter ended June 30, 2024, on Monday, August 5, 2024, after market close.

A conference call and webcast will be held at 5:00 PM (ET) / 2:00 PM (PT) to discuss the results. Investors can access the live audio webcast on the company's Investor Relations website. A live dial-in will also be available. Following the call, a replay will be accessible through September 4, 2024.

Definitive Healthcare (Nasdaq: DH) has launched a redesigned mobile app for its View Suite platform, aimed at enhancing accessibility to healthcare commercial intelligence. Announced on July 09, 2024, the new DH View Suite mobile app provides sales and marketing teams with instant access to essential data, optimizing their productivity in the field. The app offers detailed profiles of healthcare professionals and organizations, including metrics on clinical performance, finances, and more. Available for download on Apple and Android devices at no additional cost to existing customers, the app ensures that users are always prepared for client meetings and industry events.